Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2005 1
2006 2
2007 2
2008 5
2009 5
2010 5
2011 3
2012 5
2013 9
2014 11
2015 10
2016 12
2017 13
2018 11
2019 8
2020 7
2021 4
2022 5
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

94 results
Results by year
Filters applied: . Clear all
Page 1
A retrospective cohort study of patients with eosinophilia referred to a tertiary centre.
Hougaard M, Thomsen GN, Kristensen TK, Lindegaard HM, Davidsen JR, Hartmeyer GN, Kjeldsen AD, Martin-Iguacel R, Maiborg M, Assing K, Andersen CL, Broesby-Olsen S, Møller MB, Vestergaard H, Bjerrum OW. Hougaard M, et al. Among authors: lindegaard hm. Dan Med J. 2022 Mar 4;69(4):A07210558. Dan Med J. 2022. PMID: 35319447 Free article.
Erratum corrige: Increased serum levels of microfibrillar-associated protein 4 (MFAP4) are not associated with clinical synovitis in rheumatoid arthritis but may reflect underlying cardiovascular comorbidity.
Issa SF, Lindegaard HM, Lorenzen T, Junker K, Christensen AF, Hørslev-Petersen K, Holmskov U, Sorensen GL, Junker P. Issa SF, et al. Among authors: lindegaard hm. Clin Exp Rheumatol. 2022 Jan;40(1):198. doi: 10.55563/clinexprheumatol/ico144. Epub 2022 Jan 28. Clin Exp Rheumatol. 2022. PMID: 35088690 Free article. No abstract available.
Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial.
Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Christensen R, Ørnbjerg LM, Glinatsi D, Møller JM, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Larsen L, Jurik AG, Thomsen HS, Østergaard M. Møller-Bisgaard S, et al. Among authors: lindegaard h. Scand J Rheumatol. 2022 Jul;51(4):268-278. doi: 10.1080/03009742.2021.1935312. Epub 2021 Sep 2. Scand J Rheumatol. 2022. PMID: 34474649 Clinical Trial.
Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.
Glintborg B, Kringelbach T, Bolstad N, Warren DJ, Eng G, Sørensen IJ, Loft AG, Hendricks O, Hansen I, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen DV, Goll GL, Høgdall E, Gehin J, Enevold C, Nielsen CH, Krogh NS, Johansen JS, Hetland ML. Glintborg B, et al. Among authors: lindegaard h. Scand J Rheumatol. 2018 Sep;47(5):418-421. doi: 10.1080/03009742.2017.1376110. Epub 2018 Jan 9. Scand J Rheumatol. 2018. PMID: 29310493 No abstract available.
94 results